Serum miRNA-based distinct clusters define three groups of breast cancer patients with different clinicopathological and immune characteristics

AbstractBreast cancer (BCa) is a heterogeneous disease with different histological, prognostic and clinical aspects. Therefore, the need for identification of novel biomarkers for diagnosis, prognosis and monitoring of disease, as well as treatment outcome prediction remains at the forefront of research. The search for circulating elements, obtainable by simple peripheral blood withdrawal, which may serve as possible biomarkers, constitutes still a challenge. In the present study, we have evaluated the expression of 6 circulating miRNAs, (miR-16, miR-21, miR-23 α, miR-146α, miR-155 and miR-181α), in operable BCa patients, with non-metastatic, invasive ductal carcinoma, not receiving neoadjuvant chemotherapy. These miRNAs, known to be involved in both tumor cell progression and immune pathways regulation, were analyzed in relation to circulating cytokine s, tumor immune-cell infiltration and established prognostic clinicopathological characteristics. We have identified three different clusters, with overall low (C1), moderate (C2) or high (C3) expression levels of these six circulating miRNAs, which define three distinct groups of non-metastatic BCa patients characterized by different clinicopathological and immune-related characteristics, with possibly different clinical outcomes. Our data provide the proof-of-principle to support the notion that, up- or down-regulation of the same circulating miRNA may reflect different prognosis in BCa. Non etheless, the p...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research

Related Links:

ConclusionsIORT is an effective treatment option for well-selected patients with early breast cancer and can be considered for patients with lobular histology.
Source: The American Journal of Surgery - Category: Surgery Source Type: research
This study sought to evaluate the impact of RT for DCIS on mortality after SBC in a larger cohort. PATIENTS AND METHODS: Using the SEER database, 3,407 patients were identified who received breast-conserving therapy with or without RT for primary DCIS in 2000 through 2013 and subsequently developed a stage I-III invasive SBC within the same time period. Fine-Gray competing risk models were used to study the association between receipt of RT and mortality after SBC. RESULTS: Prior RT was found to be associated with higher rates of breast cancer-specific mortality (hazard ratio [HR], 1.70; 95% CI, 1.18-2.45; P=.005),...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
This study sought to identify clinicopathological factors associated with upstaging and axillary metastasis in patients preoperatively diagnosed with DCIS by CNB.Materials and MethodsThis study identified 604 patients (cT1 ‐3N0M0) with preoperative diagnosis of pure DCIS by CNB who had undergone axillary evaluation from August 2006 to December 2015 at Fudan University Shanghai Cancer Center (FUSCC). Predictors of upstaging and axillary lymph nodes metastasis were analyzed, respectively.ResultsOf all 604 patients, 121 (20.03%) and 193 (31.95%) patients were upstaged to DCIS with microinvasion (DCISM) and invasive breast c...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
ConclusionDCIS cases with duct abnormalities on ultrasound were investigated in this study. The important characteristics were as follows: (1) the distribution of ductal dilatation was focal or segmental, (2) solid parts were present in the dilated ducts, (3) the distribution of internal echoes was continuous or multiple, (4) the shape of solid echoes was broad-based and/or irregular, and (5) internal echoes were sometimes accompanied by echogenic foci. Accurate evaluation of these findings may be useful for diagnosing DCIS. Although the duct abnormalities are included in “ASSOCIATED FEATURES” in ACR BI-RADS AT...
Source: Journal of Medical Ultrasonics - Category: Radiology Source Type: research
Longer delays in surgery for ductal carcinoma in situ (DCIS) breast cancer lead to a higher risk of invasive ductal carcinoma and a slightly lower survival rate, researchers found.
Source: WebMD Health - Category: Consumer Health News Source Type: news
FRIDAY, Oct. 25, 2019 -- For each month of delay between diagnosis and surgery for ductal carcinoma in situ (DCIS), there is slightly worse survival and an increase in risk for invasive disease, according to a study published online Sept. 27 in the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Performing sentinel lymph node biopsy in older women with ductal carcinoma...Read more on AuntMinnie.comRelated Reading: Chatbots boost women's understanding of breast biopsy Leica Biosystems unveils breast tissue biopsy container Biopsy rate is low after breast cancer 3D-printed breast biopsy device boosts accuracy Women overestimate breast cancer risk, prefer biopsy
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
THURSDAY, Oct. 24, 2019 -- Delaying surgery for a noninvasive breast cancer can have dire consequences, a new study shows. Longer delays in surgery for ductal carcinoma in situ (DCIS) breast cancer lead to a higher risk of invasive ductal carcinoma...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
ConclusionsRadiomics features could be an efficient tool for the preoperative evaluation of HER-2 status in patients with breast cancer.
Source: European Journal of Radiology - Category: Radiology Source Type: research
Invasive triple ‐negative apocrine carcinoma (TNAC) of the breast is a rare type of triple‐negative breast cancer. Furthermore, the clinicopathological features, prognosis of TNAC, and the potential effect of systemic treatments on TNAC remain unclear. The purpose of the present study was to gain better knowled ge of clinicopathological features and survival differences in patients with TNAC and TNBC (non‐apocrine breast cancer), by utilizing a population wide database to enroll a large population of breast cancer. AbstractBackgroundTriple ‐negative apocrine carcinoma (TNAC) of the breast is a very rare type of bre...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
More News: Allergy & Immunology | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Ductal Carcinoma | Immunotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study